Exploring the potential of Fargesin from Chrysanthemum indicum for chronic migraine: in-silico and pharmacokinetic study
Rapuru Rushendran, Vellapandian Chitra · 2024
Read Exploring the potential of Fargesin from Chrysanthemum indicum for chronic migraine: in-silico and pharmacokinetic study by Rapuru Rushendran, Vellapandian Chitra (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11581172.txt.
Description
Rapuru Rushendran and Vellapandian Chitra probe, in a 2024 study, a plant compound as a candidate drug for chronic migraine. The illness ranks among the most disabling long-term ills in the world. Its core driver is a worn, over-sharp pain hub in the brain stem. Key marks of the disease span swelling signals and a peptide called CGRP; drugs that block CGRP work well for many. The plant, Chrysanthemum indicum, is a folk herb, but no proof sets it as a migraine care.
The compound, fargesin, was tested in computer models and lab checks, not in people. Dock tests showed it binds CGRP and a key enzyme with force. Body-use checks found strong uptake from the gut and good reach to the brain. Toxic checks looked kind. The pair calls it a lead worth more work, not a proven care.
Catalog record
| CREATOR | Rapuru Rushendran, Vellapandian Chitra |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |